MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Abbott Laboratories

Abrir

SetorSaúde

128.32 -0.9

Visão Geral

Variação de preço das ações

24h

Atual

Mín

127.11

Máximo

130.1

Indicadores-chave

By Trading Economics

Rendimento

7.6B

9.2B

Vendas

339M

11B

P/E

Médio do Setor

17.001

57.333

EPS

1.09

Rendimento de Dividendos

1.8

Margem de lucro

84.099

Funcionários

114,000

EBITDA

82M

3B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+11.42% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.80%

2.63%

Próxima data de dividendos

15 de mai. de 2025

Próxima data de ex-dividendo

14 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3B

225B

Abertura anterior

129.22

Fecho anterior

128.32

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Abbott Laboratories Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de abr. de 2025, 16:21 UTC

Ganhos

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 de abr. de 2025, 12:14 UTC

Ganhos

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

22 de jan. de 2025, 19:03 UTC

Ganhos

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22 de jan. de 2025, 18:20 UTC

Ganhos

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22 de jan. de 2025, 12:45 UTC

Ganhos

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

16 de abr. de 2025, 15:09 UTC

Conversa de Mercado

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 de abr. de 2025, 14:17 UTC

Ganhos

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 de abr. de 2025, 11:34 UTC

Ganhos

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 de abr. de 2025, 11:33 UTC

Ganhos

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 de abr. de 2025, 11:32 UTC

Ganhos

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 de abr. de 2025, 11:32 UTC

Ganhos

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 de abr. de 2025, 11:31 UTC

Ganhos

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Reaffirms Full-Yr Guidance

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q Sales $10.36B >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q Net $1.33B >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q EPS 76c >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q Adj EPS $1.09 >ABT

16 de abr. de 2025, 09:57 UTC

Ações em Alta

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

1 de fev. de 2025, 18:14 UTC

Principais Notícias

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22 de jan. de 2025, 16:40 UTC

Principais Notícias
Ganhos

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22 de jan. de 2025, 15:20 UTC

Ganhos

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22 de jan. de 2025, 15:08 UTC

Ganhos

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 de jan. de 2025, 13:51 UTC

Ganhos

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22 de jan. de 2025, 13:39 UTC

Principais Notícias
Ganhos

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 de jan. de 2025, 12:02 UTC

Ganhos

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22 de jan. de 2025, 12:01 UTC

Ganhos

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22 de jan. de 2025, 12:01 UTC

Ganhos

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22 de jan. de 2025, 12:00 UTC

Ganhos

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22 de jan. de 2025, 12:00 UTC

Ganhos

Abbott Labs 4Q Net $9.23B >ABT

Comparação entre Pares

Variação de preço

Abbott Laboratories Previsão

Preço-alvo

By TipRanks

11.42% parte superior

Previsão para 12 meses

Média 144.15 USD  11.42%

Máximo 159 USD

Mínimo 127 USD

Com base em 21 analistas de Wall Street que oferecem metas de preço de 12 meses para Abbott Laboratories - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

21 ratings

18

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

128.52 / 129.7Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.